Dossier
blood thinner
Coverage of blood thinner in the Nexus archive.
- Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations
Bristol Myers Squibb is raising its full-year outlook after blood thinner sales exceeded expectations. Strong sales of Eliquis, Camzyos, and Reblozyl pushed second-quarter revenue to $12.97 billion, surpassing analyst estimates.